New pill targets gene flaws in hard-to-treat bile duct cancer

NCT ID NCT06777316

Ongoing Disease control Sponsor: Cogent Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tried standard treatments will take the pill, and researchers will monitor safety, side effects, and how well it shrinks or controls the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma Cirrhosis, Familial, with Pulmonary Hypertension intrahepatic cholangiocarcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CHOLANGIOCARCINOMA FGFR2 GENE AMPLIFICATION FGFR2 GENE FUSION/REARRANGEMENT FGFR2 GENE SHORT VARIANTS FGFR2 GENETIC ALTERATIONS FGFR3 GENE AMPLIFICATION FGFR3 GENE FUSION/REARRANGEMENT FGFR3 GENE SHORT VARIANTS FGFR3 GENETIC ALTERATIONS INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) OTHER SOLID TUMORS, ADULT

Contacts and locations

Locations

Fox Chase cancer Center

Philadelphia, Pennsylvania, 19111, United States
Huntsman Cancer Institute - University of Utah

Salt Lake City, Utah, 84112, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic Jacksonville

Jacksonville, Florida, 32224, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Princess Margaret Cancer Centre - UHN

Toronto, Ontario, M5G 2C4, Canada
Stanford Cancer Institute

Palo Alto, California, 94305, United States
Taussig Cancer Center - Cleveland Clinic

Cleveland, Ohio, 44195, United States
Tennessee Oncology

Nashville, Tennessee, 37203, United States
The Christ Hospital

Cincinnati, Ohio, 45219, United States
University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.